1. All Products
  2. DINJ - Injectable drugs
  3. ENOXAPARIN sodium, 2,000 IU/0.2ml, syr.
Public Pricelist

ENOXAPARIN sodium, 2,000 IU/0.2ml, syr.

https://unicat.msf.org/cat/product/71011
STD DINJENOX20S

Valid Article

Former Code(s): DINJENOX4S- DINJMISC154 DINJZFR0154
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
10.2 - Medicines affecting coagulation
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
B01AB05
Anatomical Therapeutic Chemical Classification according to WHOCC
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

ENOXAPARIN

Exnoxaparin replaces nadroparin (non-standard due to supply constraints). Dosage should be adapted accordingly.

Therapeutic Action

Anticoagulant, low molecular weight heparin (LMWH)

Indications

Prevention and treatment of venous thromboembolic disease in adults

Some restricted information has been hidden. Sign in to see this information

Instructions for use

Pre-filled syringe at :

  • 10,000 IU = 100 mg enoxaparin sodium in 1 ml WPI
  • 2,000 IU = 20 mg enoxaparin sodium in 0.2 ml WPI
  • 4,000 IU = 40 mg enoxaparin sodium in 0.4 ml WPI
  • 6,000 IU = 60 mg enoxaparin sodium in 0.6 ml WPI

Equivalences:

  • Enoxaparin 0.2 ml (2000 UI) = Nadroparin 0.3 ml (2850 UI)
  • Enoxaparin 0.4 ml (4000 UI) = Nadroparin 0.4 ml (3800 UI)
  • Enoxaparin 0.6 ml (6000 UI) = Nadroparin 0.6 ml (5700 UI)

Must be given as deep SC injection:

  • Administer preferably with the patient in the supine position, in the subcutaneous cellular tissue of the anterolateral and posterolateral abdominal belt, alternating between the right and left sides.
  • Remove the protective cap from the needle.
  • Do not expel the air bubble from the syringe.
  • If a drop appears at the tip of the needle, remove the drop before injection by tapping on the body of the syringe (needle pointing downwards).
  • Insert the entire length of the needle perpendicularly and not tangentially, into a skin fold gently held between the thumb and index finger. Maintain the skin fold throughout the injection.
  • Do not rub the injection site after administration.
  • Immediately dispose of the syringe in the appropriate container. Any unused medication should be discarded.

Monitor coagulation parameters in order to adjust dose.

Check platelet counts before starting treatment and then twice a week.

Effects may be reversed by the slow IV administration of protamine, a specific heparin antagonist.

Image

Precautions for Use

Do not administer by IM route.

Storage

  • Below 25ºC
  • Do not freeze.
  • Pre-filled syringes are single-dose packs. Discard any unused product.